MX2020006284A - Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. - Google Patents
Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.Info
- Publication number
- MX2020006284A MX2020006284A MX2020006284A MX2020006284A MX2020006284A MX 2020006284 A MX2020006284 A MX 2020006284A MX 2020006284 A MX2020006284 A MX 2020006284A MX 2020006284 A MX2020006284 A MX 2020006284A MX 2020006284 A MX2020006284 A MX 2020006284A
- Authority
- MX
- Mexico
- Prior art keywords
- bis
- choline tetrathiomolybdate
- methods
- wilson disease
- treating wilson
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Se proporcionan métodos para tratar la enfermedad de Wilson con terapia de tetratiomolibdato de bis-colina. Los métodos pueden incluir administrar 15 mg o entre 30 y 90 mg de tetratiomolibdato de bis-colina una vez al día a un paciente que exhibe niveles de NCC corregido, alanina aminotransferasa (ALT), hemoglobina, plaquetas o neutrófilos que cumplen criterios establecidos. Los métodos pueden incluir modificar el tratamiento al disminuir o aumentar la dosis diaria de tetratiomolibdato de bis-colina o discontinuar el tratamiento por un período de tiempo.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762594184P | 2017-12-04 | 2017-12-04 | |
US201862646553P | 2018-03-22 | 2018-03-22 | |
US201862655568P | 2018-04-10 | 2018-04-10 | |
US201862669095P | 2018-05-09 | 2018-05-09 | |
US201862741313P | 2018-10-04 | 2018-10-04 | |
US201862750595P | 2018-10-25 | 2018-10-25 | |
PCT/EP2018/083551 WO2019110619A1 (en) | 2017-12-04 | 2018-12-04 | Bis-choline tetrathiomolybdate for treating wilson disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006284A true MX2020006284A (es) | 2021-04-12 |
Family
ID=64661349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006284A MX2020006284A (es) | 2017-12-04 | 2018-12-04 | Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. |
Country Status (16)
Country | Link |
---|---|
US (3) | US11510944B2 (es) |
EP (2) | EP4029498A1 (es) |
JP (2) | JP2021505655A (es) |
KR (1) | KR20200096798A (es) |
AU (1) | AU2018379255A1 (es) |
BR (1) | BR112020011055A2 (es) |
CA (1) | CA3084100A1 (es) |
DK (1) | DK3720433T3 (es) |
ES (1) | ES2912306T3 (es) |
HU (1) | HUE058921T2 (es) |
IL (1) | IL275115A (es) |
MX (1) | MX2020006284A (es) |
PL (1) | PL3720433T3 (es) |
PT (1) | PT3720433T (es) |
SI (1) | SI3720433T1 (es) |
WO (1) | WO2019110619A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3720433T (pt) * | 2017-12-04 | 2022-05-03 | Alexion Pharma Inc | Tetratiomolibdato de bis-colina para tratar a doença de wilson |
US11419832B2 (en) * | 2017-12-04 | 2022-08-23 | Alexion Pharmaceuticals, Inc. | Bis-choline tetrathiomolybdate for treating Wilson Disease |
EP3749417A1 (en) | 2018-02-06 | 2020-12-16 | Alexion Pharma International Operations Unlimited Company | Crystalline particles of bis-choline tetrathiomolybdate |
WO2021102379A1 (en) | 2019-11-21 | 2021-05-27 | Alexion Pharmaceuticals, Inc. | Methods of reducing neurological damage in wilson disease patients |
EP4243806A1 (en) | 2020-11-13 | 2023-09-20 | Alexion Pharmaceuticals, Inc. | Methods of treating copper metabolism-associated diseases or disorders |
US20240100088A1 (en) * | 2021-01-31 | 2024-03-28 | Alexion Pharmaceuticals, Inc. | Novel formulation for treating copper metabolism-associated diseases or disorders |
CA3228221A1 (en) | 2021-08-17 | 2023-02-23 | Brian Meltzer | Methods of treating copper metabolism-associated diseases or disorders |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7189865B2 (en) * | 2002-07-23 | 2007-03-13 | Attenuon, Llc | Thiomolybdate analogues and uses thereof |
KR20050025976A (ko) * | 2002-07-23 | 2005-03-14 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | 항-혈관형성 치료법에 사용하기 위한 테트라프로필암모늄테트라티오몰리브데이트 및 관련 화합물 |
JP2009523175A (ja) | 2006-01-10 | 2009-06-18 | パイペックス,インコーポレイテッド | 目標とされる安定な銅状態を達成及び維持して銅関連中枢神経系疾患を予防及び治療するための医薬組成物及び方法 |
US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
PT3720433T (pt) | 2017-12-04 | 2022-05-03 | Alexion Pharma Inc | Tetratiomolibdato de bis-colina para tratar a doença de wilson |
US11419832B2 (en) * | 2017-12-04 | 2022-08-23 | Alexion Pharmaceuticals, Inc. | Bis-choline tetrathiomolybdate for treating Wilson Disease |
EP3749417A1 (en) | 2018-02-06 | 2020-12-16 | Alexion Pharma International Operations Unlimited Company | Crystalline particles of bis-choline tetrathiomolybdate |
-
2018
- 2018-12-04 PT PT188156244T patent/PT3720433T/pt unknown
- 2018-12-04 JP JP2020547315A patent/JP2021505655A/ja active Pending
- 2018-12-04 HU HUE18815624A patent/HUE058921T2/hu unknown
- 2018-12-04 US US16/770,022 patent/US11510944B2/en active Active
- 2018-12-04 EP EP21215264.9A patent/EP4029498A1/en active Pending
- 2018-12-04 BR BR112020011055-8A patent/BR112020011055A2/pt unknown
- 2018-12-04 MX MX2020006284A patent/MX2020006284A/es unknown
- 2018-12-04 EP EP18815624.4A patent/EP3720433B1/en active Active
- 2018-12-04 ES ES18815624T patent/ES2912306T3/es active Active
- 2018-12-04 WO PCT/EP2018/083551 patent/WO2019110619A1/en active Application Filing
- 2018-12-04 CA CA3084100A patent/CA3084100A1/en active Pending
- 2018-12-04 DK DK18815624.4T patent/DK3720433T3/da active
- 2018-12-04 SI SI201830650T patent/SI3720433T1/sl unknown
- 2018-12-04 KR KR1020207019115A patent/KR20200096798A/ko unknown
- 2018-12-04 AU AU2018379255A patent/AU2018379255A1/en active Pending
- 2018-12-04 PL PL18815624.4T patent/PL3720433T3/pl unknown
-
2020
- 2020-06-04 IL IL275115A patent/IL275115A/en unknown
-
2021
- 2021-02-22 US US17/182,227 patent/US20210177894A1/en not_active Abandoned
-
2022
- 2022-08-23 US US17/821,786 patent/US20230070534A1/en active Pending
-
2023
- 2023-03-13 JP JP2023038205A patent/JP2023075247A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3084100A1 (en) | 2019-06-13 |
EP4029498A1 (en) | 2022-07-20 |
US20230070534A1 (en) | 2023-03-09 |
US11510944B2 (en) | 2022-11-29 |
EP3720433A1 (en) | 2020-10-14 |
JP2023075247A (ja) | 2023-05-30 |
ES2912306T3 (es) | 2022-05-25 |
WO2019110619A1 (en) | 2019-06-13 |
PT3720433T (pt) | 2022-05-03 |
US20210137972A1 (en) | 2021-05-13 |
JP2021505655A (ja) | 2021-02-18 |
AU2018379255A1 (en) | 2020-06-25 |
SI3720433T1 (sl) | 2022-09-30 |
PL3720433T3 (pl) | 2022-07-18 |
KR20200096798A (ko) | 2020-08-13 |
IL275115A (en) | 2020-07-30 |
RU2020122023A (ru) | 2022-01-10 |
DK3720433T3 (da) | 2022-05-02 |
US20210177894A1 (en) | 2021-06-17 |
BR112020011055A2 (pt) | 2020-11-17 |
EP3720433B1 (en) | 2022-02-02 |
HUE058921T2 (hu) | 2022-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020006284A (es) | Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. | |
MX2022004137A (es) | Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
MX2023005455A (es) | Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil. | |
AU2018326364A1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease | |
MX2016009231A (es) | Administracion de tasimelteon en condiciones de ayuno. | |
PH12017500392A1 (en) | Medical treatments based on anamorelin | |
PH12021550047A1 (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | |
MX2016016400A (es) | Formulaciones de oximetazolina estabilizadas y sus usos. | |
MX2021009413A (es) | Materiales y métodos para tratar una enfermedad neurodegenerativa. | |
MX2021008986A (es) | Metodos de tratamiento de un paciente con enfermedad de parkinson. | |
EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
MX2019004200A (es) | Terapia de combinacion. | |
MX2019008076A (es) | Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada. | |
WO2017189906A8 (en) | Immune-based treatment of kras-variant cancer patients | |
AU2020360413A8 (en) | Methods of treating conditions related to the S1P1 receptor | |
MX2022003628A (es) | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente. | |
MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
EP4245366A3 (en) | Migalastat for treating fabry patients having renal impairment | |
AR111971A1 (es) | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal | |
MX2022002947A (es) | Avocatina b para el tratamiento de enfermedades y afecciones. | |
UA127590U (uk) | Спосіб лікування хворих на псоріаз | |
MDS20160124U2 (ro) | Metodă de profilaxie a limforeii prolongate în tratamentul radical al cancerului glandei mamare la pacientele cu diabet zaharat tip 2 | |
Fabiny | Ask the doctor. I recently took antibiotics to treat an oral infection and as a result developed a vaginal yeast infection. Can I treat it myself, and what are the most effective options? |